share_log

EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target

Benzinga ·  Nov 7 21:32  · Ratings

EF Hutton analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $24 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment